Annovis Bio, Inc. (FRA:07X)

Germany flag Germany · Delayed Price · Currency is EUR
3.920
+0.225 (6.09%)
At close: Dec 4, 2025
-42.86%
Market Cap 103.66M
Revenue (ttm) n/a
Net Income (ttm) -21.21M
Shares Out n/a
EPS (ttm) -1.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 2,673
Open 3.920
Previous Close 3.695
Day's Range 3.920 - 3.920
52-Week Range 1.050 - 6.120
Beta n/a
RSI 64.04
Earnings Date Nov 20, 2025

About Annovis Bio

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer’s disease, as well as in phase 3 to treat parkinson’s disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzhei... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Employees 15
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 07X
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.